Skip to Main Content

Paper Details

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
Nephrol Dial Transplant
144
2017
CKD, FG-4592, HIF, HIF-PHI, Hb, NDD, anemia, anemia of chronic kidney disease, cholesterol, epoetin, epoetin alfa, hemoglobin, hepcidin, hypoxia-inducible factor, hypoxia-inducible factor prolyl hydroxylase, iron, participants, patients, prolyl, roxadustat, transcription factor, transferrin
Author NameAffiliation
Nan ChenInstitute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Lynda A SzczechInc.
  • 1 - 2

Datasets

Release 1.2